Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery

Next Previous
Trial Profile

Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Suratadenoturev (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 27 Jan 2025 According to an Oncolys Biopharma media release, Dr. Geoffrey Ku from Memorial Kettering Cancer Center is the Lead PI of this study.
  • 27 Jan 2025 According to an Oncolys Biopharma media release, The 100% cCR rate of OBP-301 when combined with CRT in the 13 patients who underwent restaging compares favorably to the historical control of 58% from the control arm of the phase III NRG/RTOG 0436 study. The Lead PI Dr. Geoffrey Ku looks forward to continuing this investigation in the next randomized study in partnership with Oncolys Biopharma.
  • 27 Jan 2025 According to an Oncolys Biopharma media release, final safety and clinical response data from this study were presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) 2025 in San Francisco, California.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top